Data & Technology

A systematic review determines if adult patients with language barriers are less likely to use the video-based virtual care option, while exploring equity and accessibility gaps when it comes to telehealth.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses how uncertainty can help reshape the way organizations prioritize supply chain investments.

In the fourth part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, explains how migrating to cloud-based systems can help overcome this challenge.

In the third part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, comments on the role of automation and GenAI evolving in workforce development.

In the second part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses the common misconceptions supply chain leaders might have around the term, and why the processes around optimization need to change.

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications.

This serialization system represents a business imperative that yields significant competitive advantages.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled delivery of highly individualized treatments.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

In the third part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, dives into the barriers limiting AI and automation’s widespread adoption in R&D.

Ruth Beadle, head, global supply chain, Sanofi, discusses the company’s multi-year effort to build an AI-powered, end-to-end supply chain focused on improving service, resilience, and cost efficiency.

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

By embracing practical, human-centered use cases, life sciences companies are breaking free from GenAI “pilotitis” and demonstrating how scalable AI solutions can help transform patient care and provider efficiency.

Exploring the importance of contract development and manufacturing organizations in advancing the latest technology for effective delivery of temperature-sensitive medicines.

Steffen Lang, president, operations, executive committee member, Novartis, discusses what to expect from Novartis over the next decade in terms of technological innovations.

How can stakeholders prepare for changing therapy requirements?

A keynote presentation describes how supply chain visibility should rely on digital capabilities.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, shares his thoughts on the rumors that RFK Jr. could potentially ban DTC advertising.

Taking stock of today's gains and tomorrow's potential for generative artificial intelligence in reshaping the industry.

The parties aim to create an end-to-end digital thread that links research data all the way through to life sciences manufacturing.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, uncovers the main reasons why 52% of respondents choose DTC online prescription platforms.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, explains the rise in patients turning to DTC platforms following insurance denials.

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, addresses how AI can help support pharma leaders with managing their supply chains and addressing potential material shortages.